Drug
Gsk1349572
Gsk1349572: highest development phase Phase 2, developed by GlaxoSmithKline, Shionogi. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- GlaxoSmithKline, Shionogi
Trials
| Drug | Phase | Indication |
|---|---|---|
| GSK1349572 NCT00708110 | Phase 2 | Infection, Human Immunodeficiency Virus |
| GSK1349572 NCT01332565 | Phase 1 | Infection, Human Immunodeficiency Virus |
| GSK1349572 NCT01231542 | Phase 1 | Infection, Human Immunodeficiency Virus |
Latest
No recent events.
Follow Gsk1349572 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.